Alx oncology reports fourth quarter and full year 2024 financial results and provides corporate update

– presented positive updated data from aspen-06 phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with her2-positive gastric cancer in an oral presentation at 2025 asco gi

ALXO Ratings Summary

ALXO Quant Ranking